Allograft for myeloma: Examining pieces of the Jigsaw Puzzle

Ehsan Malek, Najla El-Jurdi, Nicolaus Kröger, Marcos de Lima

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Multiple myeloma (MM) cure remains elusive despite the availability of newer anti-myeloma agents. Patients with high-risk disease often suffer from early relapse and short survival. Allogeneic hematopoietic cell transplantation (allo-HCT) is an "immune-based" therapy that has the potential to offer long-term remission in a subgroup of patients, at the expense of high rates of transplant-related morbidity and mortality. Donor lymphocyte infusion (DLI) upon disease relapse after allo-HCT is able to generate an anti-myeloma response suggestive of a graft-versus-myeloma effect. Allo-HCT provides a robust platform for additional immune-based therapy upon relapse including DLI and, maintenance with immunomodulatory drugs and immunosuppressive therapy. There have been conflicting findings from randomized prospective trials questioning the role of allo-HCT. However, to this date, allo-HCT remains the only potential curable treatment for MM and its therapeutic role needs to be better defined especially for patients with high-risk disease. This review examines different aspects of this treatment and summarizes ongoing attempts at improving its therapeutic index.

Original languageEnglish (US)
Article number287
JournalFrontiers in Oncology
Issue numberDEC
StatePublished - Dec 11 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 Malek, El-Jurdi, Kröger and de Lima.


  • Allogeneic
  • Allograft
  • Allograft for myeloma
  • Hematopoietic stem cells
  • Multiple myeloma


Dive into the research topics of 'Allograft for myeloma: Examining pieces of the Jigsaw Puzzle'. Together they form a unique fingerprint.

Cite this